论文部分内容阅读
目的观察地特胰岛素联合瑞格列奈在治疗新诊断T2DM患者中的疗效及安全性。方法选择HbA1c≥8.5%的新诊断T2DM患者56例,给予地特胰岛素联合瑞格列奈治疗12周,比较治疗前后FPG、2hPG、HbA1c、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)、血脂、体重及低血糖发生情况。结果治疗后,FPG、2hPG、HbA1c、TG、LDL-C及HOMA-IR显著降低(P<0.05);HOMA-β显著增高(P<0.01);体重无明显差异。治疗中低血糖发生率低,无严重低血糖事件发生。结论地特胰岛素联合瑞格列奈治疗可明显改善新诊断T2DM患者糖脂毒性,逆转受损的β细胞功能,且安全性好。
Objective To observe the efficacy and safety of detemir plus repaglinide in the treatment of newly diagnosed T2DM patients. Methods Fifty-six newly diagnosed T2DM patients with HbA1c≥8.5% were treated with detemir and repaglinide for 12 weeks. FPG, 2hPG, HbA1c, HOMA-IR, beta-cell function index (HOMA-β), lipids, body weight and hypoglycemia. Results After treatment, the levels of FPG, 2hPG, HbA1c, TG, LDL-C and HOMA-IR were significantly decreased (P <0.05); HOMA-β was significantly increased (P <0.01); Low incidence of hypoglycemia in treatment, no serious hypoglycemic events. Conclusion Detemir insulin combined with repaglinide can significantly improve the glycometabolism of newly diagnosed T2DM patients and reverse the function of damaged β cells with good safety.